AN OPEN-LABEL, EXTENSION (ROLLOVER)STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL

Trial Profile

AN OPEN-LABEL, EXTENSION (ROLLOVER)STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Feb 2018 Planned End Date changed from 28 Feb 2019 to 24 Jun 2020.
    • 13 Feb 2018 Planned primary completion date changed from 28 Feb 2019 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top